MiRNAs
The Tiny Molecules Revolutionising Diagnostics in Heart Disease and Cancer
Srinivasulu Yerukala Sathipati, Associate Research Scientist, Marshfield Clinic Research Institute in Marshfield
Param Sharma, Electrophysiologist, Marshfield Clinic Health System
Rohit Sharma, Surgical Oncologist, Marshfield Clinic Health System
Terrie Kitchner, Research Coordinator
Luke Moat, Research Associate
miRNAs, pivotal in gene regulation, are emerging as transformative biomarkers for cardiovascular diseases and cancers. The recent Nobel Prize awarded to Victor Ambros and Gary Ruvkun for their breakthrough discovery of miRNA has heightened enthusiasm and focus on miRNA biomarker research, unlocking new opportunities for early detection and personalised medicine.
1. Why are miRNAs emerging as a significant focus area in cancer diagnostics, and what advantages do they bring for early disease detection?
miRNAs are gaining prominence in cancer diagnostics due to their pivotal role in regulating gene expression and their unique expression patterns that distinguish cancerous from healthy tissues. These small, non-coding RNA molecules act as master regulators in key biological processes, and their dysregulation often correlates with cancer development and progression. Unlike other biomarkers, miRNAs exhibit remarkable stability in biofluids such as blood, saliva, and urine, making them ideal candidates for minimally invasive diagnostics. This stability allows for reliable detection even in challenging clinical settings.
In our cancer studies, particularly in collaboration with Dr. Rohit Sharma, we are working to identify specific circulating miRNA signatures that can detect cancer at its earliest stages. Early detection is crucial in oncology, as it significantly improves patient outcomes by enabling timely and targeted interventions. The miRNA-based diagnostic tools we are developing aim to overcome limitations in traditional methods, such as imaging or biopsy, by offering a more accessible and scalable approach to cancer screening.
The significance of miRNAs in medicine was underscored by the awarding of the 2024 Nobel Prize in Physiology or Medicine to Victor Ambros and Gary Ruvkun for their discovery of microRNAs and their role in post-transcriptional gene regulation. This recognition highlights the profound impact of miRNA research on our understanding of gene regulation and its potential applications in diagnostics and therapeutics.
2. How is your research utilising miRNAs to assess risks in cardiovascular patients, particularly those with Implantable Cardioverter Defibrillator (ICDs)?
In collaboration with Dr. Param Sharma, a cardiologist, our research focuses on analysing miRNA profiles in myocardial infarction patients with ICD implants. ICDs are life-saving devices that prevent sudden cardiac death by delivering shocks during life-threatening arrhythmias. However, not all patients benefit equally from these devices, and many receive unnecessary implants, leading to increased healthcare costs and potential patient distress.
Our goal is to identify miRNA biomarkers that can predict which patients are most likely to experience shocks within a year of implantation. By integrating miRNA data with clinical outcomes, we aim to develop a risk stratification model that enhances decision-making around ICD placement. This approach not only improves patient care by tailoring interventions to those who need them most but also reduces unnecessary procedures and healthcare costs. Early findings suggest that miRNA profiling could save thousands of dollars per case by avoiding unnecessary implants and focusing resources on high-risk patients.
3. Can you explain how cancer and cardiovascular diseases are connected and what inspires you to pursue research in both fields?
Cancer and cardiovascular diseases, though distinct, share several overlapping molecular mechanisms. Both involve complex pathways such as inflammation, oxidative stress, angiogenesis, and apoptosis, which are often dysregulated in response to genetic mutations and environmental factors. miRNAs, as master regulators of gene expression, play critical roles in these processes. For instance, certain miRNAs implicated in tumor growth also influence cardiovascular function, highlighting their dual roles in both diseases.
My inspiration to pursue research in these two fields stems from the opportunity to leverage these shared pathways to develop diagnostic tools that benefit patients with either condition. By focusing on miRNAs as biomarkers, I aim to create minimally invasive assays that can detect early signs of both cancer and cardiovascular diseases. This interdisciplinary approach not only enhances our understanding of these conditions but also allows us to translate findings across fields, fostering innovation in diagnostics and patient care. The Nobel Prize awarded to Victor Ambros and Gary Ruvkun for their discovery of miRNAs further inspires this work, as it validates the central role of miRNAs in linking diverse biological processes and diseases.
4. What unique challenges do you encounter in miRNA research when studying diseases as distinct as cancer and cardiovascular conditions?
One of the most significant challenges in miRNA research is the context-specific role of miRNAs in different diseases. In cancer, miRNAs can act as oncogenes or tumour suppressors, influencing cell proliferation, apoptosis, and metastasis. On the other hand, in cardiovascular diseases, miRNAs are key regulators of inflammation, vascular remodeling, and tissue repair. This functional divergence necessitates a tailored approach to study miRNAs in each disease context. Another challenge is the variability in miRNA extraction, quantification, and normalisation, which can impact reproducibility. To address this, we utilise a high-throughput miRNA extraction and quantification system that ensures consistency and reliability across experiments. Collaborating with clinicians like Dr. Rohit Sharma (a surgical oncologist) and Dr. Param Sharma (a cardiologist) also helps us navigate these complexities. Their clinical expertise enables us to ask the right research questions and interpret findings with translational relevance. These interdisciplinary efforts strengthen our approach and enhance the robustness of our research.
5. What role does machine learning play in your work on miRNA biomarkers, and how does it enhance predictive accuracy?
Machine learning is integral to our research, particularly in analysing the vast and complex datasets generated from miRNA profiles and clinical records. Traditional statistical methods often fall short in uncovering subtle patterns or interactions within such high-dimensional data, but machine learning excels in these areas. We have developed an evolutionary learning (EL)-based biomarker discovery platform that combines miRNA data with clinical and genomic data. This platform identifies key miRNA biomarkers and integrates them into predictive models with enhanced accuracy and robustness. By iteratively optimizing feature selection and model parameters, the EL algorithm provides insights into disease mechanisms and patient stratification. This approach has been instrumental in improving the precision of disease prediction and risk assessment, allowing us to address critical gaps in early diagnosis and personalized treatment strategies.
6. What potential does miRNA hold for transforming the treatment landscape, particularly in early-stage cancer?
miRNAs represent a paradigm shift in early-stage cancer diagnostics and therapeutics. Their stability in biofluids, such as blood and saliva, and their ability to reflect the underlying molecular changes make them ideal candidates for non-invasive diagnostic tools. Our research focuses on identifying circulating miRNAs that can serve as early biomarkers for cancer detection, even before clinical symptoms appear. By enabling earlier and more accurate diagnosis, miRNA-based assays have the potential to significantly improve patient outcomes through timely intervention. Moreover, miRNAs can guide personalised therapy by providing insights into tumor biology and treatment response. For example, profiling tumour-specific miRNA signatures can help identify patients who are more likely to benefit from targeted therapies or immunotherapies.
Our ultimate goal is to translate these findings into clinically viable diagnostic tools that are accessible, cost-effective, and capable of transforming the standard of care for early-stage cancer patients.
7. How does your background in breast cancer miRNA research inform your approach to studying cardiovascular disease?
My extensive work in breast cancer miRNA research has provided me with a deep understanding of the nuances of miRNA biology, including their role in disease progression, diagnostic potential, and therapeutic implications. This foundation has been invaluable in expanding my research to cardiovascular diseases. The technical expertise gained in miRNA extraction, quantification, and data analysis is highly transferable, enabling us to establish robust pipelines for studying miRNAs in cardiovascular contexts. While the disease mechanisms differ, the underlying principles of miRNA research remain consistent, allowing us to adapt and optimise our methods effectively. Additionally, lessons learned from addressing challenges in cancer research—such as managing sample variability and integrating multi-omics data— inform our strategies in cardiovascular studies. This cross-disciplinary approach enhances the predictive models we develop and fosters innovation in both fields.
8. Are there any key collaborators or partnerships that enhance your miRNA research in cancer and cardiovascular diseases?
Collaboration is central to our work, especially in tackling complex diseases. I am fortunate to work with outstanding collaborators who bring unique perspectives and skills to our projects. Dr. Rohit Sharma, a surgical oncologist, and Dr. Param Sharma, a cardiologist, provide invaluable clinical insights that shape our research questions and ensure translational relevance. Beyond clinical collaborations, we partner with Prof. Shinn-Ying Ho from National Yang Ming Chiao Tung University in Taiwan. His expertise in image analysis and bioinformatics has been instrumental in integrating imaging data with miRNA profiles, advancing our understanding of disease mechanisms.
Our team also includes clinical residents and fellows who contribute to data collection and interpretation, ensuring that our research is grounded in real-world clinical challenges. We are actively seeking industry and academic partnerships to facilitate the translation of our findings into practical applications, such as diagnostic assays or therapeutic tools. These collaborations not only enhance the impact of our work but also accelerate the development of innovative miRNA-based solutions for cancer and cardiovascular diseases.
References:
(1) Yerukala Sathipati S, Jeong S, Sharma P, Mayer J, Sharma R, Ho SY, Hebbring S. Exploring prognostic implications of miRNA signatures and telomere maintenance genes in kidney cancer. Mol Ther Oncol. 2024 Sep 10;32(4):200874. doi: 10.1016/j.omton.2024.200874. PMID: 39399813; PMCID: PMC11467672.
(2) Yerukala Sathipati S, Tonia Carter, Deepa Soodi, Nwaedozie Somto, Sanjay K Shukla, John Petronovich, Glurich Ingrid, John Braxton, Param Sharma. MicroRNA signature predicts post-operative atrial fibrillation after coronary artery bypass grafting. medRxiv 2024.06.21.24309328; doi: https://doi.org/10.1101/2024.06.21.24309328.
(3) Yerukala Sathipati S, Tsai MJ, Aimalla N, Moat L, Shukla SK, Allaire P,.Ho SY [including Hebbring S, Sharma R.] An evolutionary learning-based method for identifying a circulating miRNA signature for breast cancer diagnosis prediction. NAR Genom Bioinform. 2024 March;6(1):lqae022. doi: 10.1093/nargab/lqae022. PMCID: PMC10894035.
(4) Yerukala Sathipati S, Tonia Carter, Deepa Soodi, Nwaedozie Somto, Sanjay K Shukla, John Petronovich, Glurich Ingrid, John Braxton, Param Sharma. MicroRNA signature predicts post-operative atrial fibrillation after coronary artery bypass grafting. medRxiv 2024.06.21.24309328; doi: https://doi.org/10.1101/2024.06.21.24309328.
(5) Yerukala Sathipati S, Ming-Ju T, Shukla, S, Shinn-Ying H. Artificial intelligence-driven pan-cancer analysis reveals miRNA signatures for cancer stage prediction. Human Genetics and Genomics Advances. 2023 July; 4(3):100190. doi: 10.1016/j.xhgg.2023.100190. PMCID: PMC10130501. PubMed ID: 37124139.
Author Bio
Dr. Srinivasulu Yerukala Sathipati, PhD, is an associate research scientist at Marshfield Clinic research Institute in Marshfield, WI, USA. He specializes in miRNA-based diagnostics for cancer and cardiovascular diseases. With expertise in machine learning and bioinformatics, Dr. Sathipati has developed innovative approaches to leverage miRNAs as predictive tools in healthcare. His research involves collaboration with leading experts and clinical teams, focusing on advancing miRNA applications in cancer detection and cardiovascular risk assessment.
Dr. Param Sharma, MD, FACC, FHRS, is an electrophysiologist at Marshfield Clinic Health System, Marshfield, WI, USA. He specializes in treating patients with abnormal heart rythms and has strong commintment to medical education, serving as clinical adjunct professor for the University of Wisconsin School of Medicine and Public Health. Recognized for his dedication to teaching, Dr. Sharma has received the prestigious. Dr. G.E. Magnin Teaching Award for excellence in medical education. His research interests include exploring the use of miRNAs for advancing cardiovascular disease diagnostics, and he is currently leading several projects focused on this area.
Dr. Rohit Sharma, MD, MS, FACS, FRCS (Glas), MBA, is a Surgical Oncologist at Marshfield Clinic Health System, Marshfield, WI, USA. He has been in practice for more than 27 years. He is an active member of professional societies for American Association for Cancer Research, American College of Healthcare Executives, American College of Surgeons, American Medical Association, American Society of Breast Surgeons, American Society of Clinical Oncology, Society for Surgery of the Alimentary Tract, Society of American Gastrointestinal Endoscopic Surgeons, and Society of Surgical Oncology. His research interests include developing minimally invasive cancer screening methods for advancing cancer diagnostics.
Terrie Kitchner, research coordinator, is an expert in recruiting participants and is currently leading participant enrollment. Her extensive experience in patient engagement and recruitment ensures that the data collected is high-quality, representative data essential for the analysis.
Luke Moat, a research associate and biochemist at Marshfield Clinic Research Institute, specialises in molecular biology and is responsible for all benchwork, from miRNA extraction from blood samples to miRNA profiling.
